Bronwyn Brophy is appointed new CEO of Vitrolife AB (publ)

Rhea-AI Summary

Bronwyn Brophy has been appointed as the new CEO of Vitrolife (OTC-PINK:VTRLY), starting August 1, 2023. Brophy brings substantial leadership experience from previous roles at Thermo Fisher Scientific, Medtronic, and Johnson & Johnson. She will replace Thomas Axelsson, who will step down on March 31, 2023, with Jón Sigurdsson serving as interim CEO until Brophy's arrival. The board expects Brophy's experience will drive growth and enhance shareholder value. Sigurdsson praised her international experience as vital for the company’s future.

Positive

• Bronwyn Brophy's extensive leadership experience in Life Science and Medtech.
• Her appointment is seen as a strategic move to enhance shareholder value.

Negative

• Concerns regarding leadership continuity during the transition period.

Bronwyn Brophy has an impressive track record as a leader of global Life science and Medtech businesses. The Board of directors find Bronwyn Brophy to be an exceptional candidate to effectuate Vitrolife's strategy to reach the company's full potential and thereby create increased shareholder value.

GOTHENBURG, Sweden, Feb. 1, 2023 /PRNewswire/ -- Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The last years within Thermo Fischer Bronwyn Brophy was heading the Immunodiagnostics Division globally and before that served as President of the EMEA region.

Bronwyn Brophy will join the company at the latest on 1 August 2023.

As notified 12 September 2022, Thomas Axelsson will leave his position as CEO. This is expected to occur 31 March 2023. At that time Jón Sigurdsson, today Chairman of the board, will assume the position as interim CEO until Bronwyn Brophy starts her appointment. Consequently, the board of directors has appointed the current board member Henrik Blomquist as chairman of the board until the annual general meeting 27 April 2023.

Jón Sigurdsson, chairman of the board, says: "I am very pleased that we have been able to assign Bronwyn Brophy as CEO. She has an extensive experience of developing businesses and has a wide international experience which is important for Vitrolife. Again, I would like to thank Thomas Axelsson for an excellent job done for Vitrolife and for our great cooperation."

Bronwyn Brophy comments the appointment: "I am very honored to the appointment as new CEO of Vitrolife. I believe the company has a very exciting future with great growth potential with strong distributors and global partners".

Contact persons:

Thomas Axelsson, CEO, phone: +46 31 721 80 01
Patrik Tolf, CFO, phone: +46 31 766 90 21

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.15 am CET on February 1, 2023.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

The following files are available for download:

https://mb.cision.com/Main/1031/3706827/1818881.pdf

Bronwyn Brophy is appointed new CEO of Vitrolife AB (publ)

 

View original content:https://www.prnewswire.com/news-releases/bronwyn-brophy-is-appointed-new-ceo-of-vitrolife-ab-publ-301735771.html

SOURCE Vitrolife AB (publ)

FAQ

Who is the new CEO of Vitrolife (VTRLY)?

Bronwyn Brophy has been appointed as the new CEO of Vitrolife.

When will Bronwyn Brophy start her position as CEO?

She will start her position on August 1, 2023.

Who is the interim CEO of Vitrolife until Bronwyn Brophy takes over?

Jón Sigurdsson will serve as interim CEO until Bronwyn Brophy's appointment.

What previous companies did Bronwyn Brophy work for?

She has held leadership roles at Thermo Fisher Scientific, Medtronic, and Johnson & Johnson.

What is the expected impact of Bronwyn Brophy's appointment on Vitrolife?

Her extensive experience is expected to drive growth and enhance shareholder value.